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evaluation of the VOICE risk score (HPTN 068)
Abstract
INTRODUCTION: To maximize impact and minimize costs, antiretroviral pre-exposure prophylaxis
(PrEP) interventions should be offered to those at highest risk for HIV infection. The risk score derived from
the VOICE trial is one tool currently being utilized to determine eligibility in adolescent PrEP trials in sub-
Saharan Africa. This study is aimed at evaluating the utility of the risk score in predicting HIV incidence
among a cohort of adolescent girls in rural South Africa.
METHODS: We utilized data from HIV Prevention Trials Network (HPTN) 068, a phase III randomized
controlled trial conducted in rural Mpumalanga province, South Africa. School-attending young women aged
13 to 20 years were enrolled into the trial from 2011 to 2012 and followed for up to three years. A risk score
based on individual-level risk factors measured at enrolment was calculated for HPTN 068 participants who
completed a one-year follow-up visit and were HIV seronegative at enrolment. Possible scores ranged from 0
to 10. A proportional hazards model was then used to determine if risk score at enrolment was predictive of
incident HIV infection at follow-up and an area under the curve analysis was used to examine the predictive
ability of the score.
RESULTS AND DISCUSSION: The risk score had limited variability in the HPTN 068 sample. Scores ≥5
identified 85% of incident infections from 94% of the sample, compared to the VOICE sample in which scores
≥5 identified 91% of incident infections from only 64% of participants. The risk score did not predict HIV
incidence after one year of follow-up (hazard ratio = 1.029; 95% confidence interval (CI): 0.704, 1.503, p =
.884) and showed poor predictive ability (area under the curve = 0.55; 95% CI: 0.44, 0.65). Certain individual
risk factors that comprise the risk score may be context specific or not relevant for adolescent populations.
Additional factors should be considered when assessing risk for the purposes of determining PrEP eligibility.
CONCLUSIONS: The VOICE risk score demonstrated low utility to predict HIV incidence in the HPTN
068 sample. Findings highlight the need for an age and developmentally appropriate tool for assessing risk for
HIV infection among adolescents. Use of the VOICE risk score for determining PrEP eligibility in younger
populations should be carefully considered.
Disciplines
Education | Social and Behavioral Sciences
Publication Details
Giovenco, D., Pettifor, A., MacPhail, C., Kahn, K., Wagner, R., Piwowar-Manning, E., Wang, J. & Hughes, J. P.
(2019). Assessing risk for HIV infection among adolescent girls in South Africa: an evaluation of the VOICE
risk score (HPTN 068). Journal of the International AIDS Society, 22 (7), e25359-1-e25359-6.
Authors
Danielle Giovenco, Audrey Pettifor, Catherine L. Mac Phail, Kathleen Kahn, Ryan Wagner, Estelle Piwowar-
Manning, Jing Wang, and James Hughes
This journal article is available at Research Online: https://ro.uow.edu.au/sspapers/4502
SHORT REPORT
Assessing risk for HIV infection among adolescent girls in South
Africa: an evaluation of the VOICE risk score (HPTN 068)
Danielle Giovenco1§ , Audrey Pettifor1 , Catherine MacPhail2,3, Kathleen Kahn3, Ryan Wagner3,
Estelle Piwowar-Manning4, Jing Wang5 and James P Hughes6
§Corresponding author: Danielle Giovenco, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, CB #7435, Chapel Hill, NC 27599-7435, USA. (dgiovenco@unc.edu)
Abstract
Introduction: To maximize impact and minimize costs, antiretroviral pre-exposure prophylaxis (PrEP) interventions should be
offered to those at highest risk for HIV infection. The risk score derived from the VOICE trial is one tool currently being uti-
lized to determine eligibility in adolescent PrEP trials in sub-Saharan Africa. This study is aimed at evaluating the utility of the
risk score in predicting HIV incidence among a cohort of adolescent girls in rural South Africa.
Methods: We utilized data from HIV Prevention Trials Network (HPTN) 068, a phase III randomized controlled trial con-
ducted in rural Mpumalanga province, South Africa. School-attending young women aged 13 to 20 years were enrolled into
the trial from 2011 to 2012 and followed for up to three years. A risk score based on individual-level risk factors measured
at enrolment was calculated for HPTN 068 participants who completed a one-year follow-up visit and were HIV seronegative
at enrolment. Possible scores ranged from 0 to 10. A proportional hazards model was then used to determine if risk score at
enrolment was predictive of incident HIV infection at follow-up and an area under the curve analysis was used to examine the
predictive ability of the score.
Results and Discussion: The risk score had limited variability in the HPTN 068 sample. Scores ≥5 identified 85% of incident
infections from 94% of the sample, compared to the VOICE sample in which scores ≥5 identified 91% of incident infections
from only 64% of participants. The risk score did not predict HIV incidence after one year of follow-up (hazard
ratio = 1.029; 95% confidence interval (CI): 0.704, 1.503, p = .884) and showed poor predictive ability (area under the
curve = 0.55; 95% CI: 0.44, 0.65). Certain individual risk factors that comprise the risk score may be context specific or not
relevant for adolescent populations. Additional factors should be considered when assessing risk for the purposes of deter-
mining PrEP eligibility.
Conclusions: The VOICE risk score demonstrated low utility to predict HIV incidence in the HPTN 068 sample. Findings high-
light the need for an age and developmentally appropriate tool for assessing risk for HIV infection among adolescents. Use of
the VOICE risk score for determining PrEP eligibility in younger populations should be carefully considered.
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1 | INTRODUCTION
Biomedical HIV prevention technologies, such as antiretroviral
pre-exposure prophylaxis (PrEP), hold enormous potential to
substantially reduce HIV acquisition in high-risk populations
globally. To maximize impact and minimize costs, PrEP inter-
ventions should be offered to those at highest risk for HIV
infection. HIV risk assessment tools have been generated for
several key populations, including heterosexual HIV serodis-
cordant couples [1], men who have sex with men [2,3], and
pregnant and postpartum women [4].
In attempts to identify African women at greatest risk for
HIV infection, Balkus et al. [5] developed and validated a risk
assessment tool to predict one-year risk of HIV acquisition
among African women in generalized HIV epidemic settings,
where PrEP scale-up is especially warranted. The authors anal-
ysed data from three randomized placebo-controlled trials of
biomedical HIV prevention technologies, including the VOICE
trial, HIV Prevention Trials Network (HPTN) 035, and FEM-
PrEP. The VOICE trial assessed the safety and effectiveness of
daily oral tenofovir disoproxil fumarate (TDF), oral TDF/
emtricitabine (FTC), and 1% vaginal tenofovir gel as PrEP for
HIV prevention [6]. HPTN 035 and FEM-PrEP tested the
effectiveness of a microbicide gel and oral TDF/FTC respec-
tively [7,8]. Baseline demographic, behavioural, clinical and
self-reported male partner characteristics from the VOICE
study were used to identify a discrete set of easy-to-measure
characteristics that were thought to be predictive of HIV
acquisition. These individual-level risk factors were assigned a
value and a total risk score for each participant was calculated
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by taking the sum of values for each risk factor, with possible
scores ranging from 0 to 11. The risk score was then exter-
nally validated by separately applying it to the HPTN 035 and
FEM-PrEP study populations. The VOICE trial, HPTN 035,
and FEM-PrEP all included women ≥18 years of age (Median
ages = 23-25 years).
Adolescents and young adults aged 15-24 years in sub-
Saharan Africa account for over one-third all new infections,
with over twice as many new infections among young women
than young men [9]. Adolescents <18 years of age, however,
remain inadequately represented in biomedical HIV preven-
tion research posing a significant challenge for integrating
strategies such as PrEP into effective combination prevention
packages [10]. To address this need, several open-label PrEP
demonstration studies aimed at understanding key barriers
and facilitators to PrEP acceptability, uptake, and adherence
among adolescents at highest risk for HIV infection are cur-
rently planned or ongoing in sub-Saharan Africa [11]. The risk
score derived from the VOICE trial is one tool currently being
utilized to determine PrEP eligibility in adolescent trials [12].
Therefore, this research was aimed at validating the risk score
for use in a population of adolescent girls in rural South
Africa.
2 | METHODS
Data from HPTN 068 was utilized for this analysis. HPTN
068 was a phase III randomized controlled trial conducted in
Mpumalanga province, South Africa within the Agincourt
Health and socio-Demographic Surveillance System site. This
region is a rural area characterized by high HIV prevalence,
poverty and migration for work [13]. The aim of the study was
to assess the impact of a cash transfer, conditioned on school
attendance, on HIV incidence. School-attending young women
aged 13 to 20 years, who were not married or pregnant, were
enrolled into the study between March 2011 and December
2012 and followed for up to three years. Written informed
consent from a primary caregiver (parent or legal guardian)
and written informed consent/assent from each young woman
was obtained prior to participation. More information on
HPTN 068 study methods are detailed elsewhere [14,15].
The risk score derived from the VOICE trial, which incorpo-
rates age, living with a primary partner, having a partner pro-
vide financial or material support, having partner who has
other partners, any alcohol use in the past three months, and
herpes simplex virus type 2 (HSV-2) serostatus, was calculated
at baseline for participants with complete data for individual-
level risk factors who were HIV seronegative. HPTN 068 par-
ticipants were asked to provide information on their current
partner(s). Participants were asked if they were currently liv-
ing with each partner (yes/no), if they were receiving financial
(“has [your partner] ever given you money?”) or material (“has
[your partner] ever given things, like groceries, clothes or air-
time, that help you get by”) support from each partner (yes/
no), and if each partner had other sexual partners (yes/no/
don’t know). If HPTN 068 participants reported “yes” or “don’t
know” for least one partner, they were categorized as such
for each risk factor. HPTN 068 did not collect data on curable
sexually transmitted infections (STIs); therefore, the full risk
score was adapted to exclude this risk factor (range = 0-10).
See Appendix for the full risk score derived from the VOICE
trial.
Consistent with the VOICE risk score derivation and valida-
tion analyses, and when we hypothesized that the predictive
ability of baseline risk factors would be strongest, we exam-
ined the relationship between baseline risk score and HIV
incidence after one year of follow-up. One-year HIV incidence
was observed for participants with a follow-up visit occurring
between 6 and 18 months post-baseline. The number of inci-
dent infections was examined by risk score and a proportional
hazards model was used to determine if baseline risk score
was predictive of incident HIV infection. The area under the
receiver operating characteristic curve (AUC) was used to
assess the performance of the risk score in the HPTN 068
study population and the sensitivity and specificity at different
risk score cut-points were calculated.
3 | RESULTS AND DISCUSSION
In the HPTN 068 sample, 99% of participants had complete
baseline data for individual-level risk factors (N = 2503/
2533). Included in the analysis were 2178 participants with
a one-year follow-up visit who were HIV seronegative at
baseline. Participant demographic and behavioural character-
istics are shown in Table 1. The median age of participants
was 15 years (interquartile range = 14-17 years). The major-
ity of participants (89%) were under 18 years of age.
Approximately 31% of participants had a “boyfriend or main
partner,” 24% had at least one sex partner in their lifetime,
and 22% had at least one sex partner in the past three
months.
The distribution of HPTN 068 participants across individual
risk factors that comprise the risk score at baseline are pre-
sented in Table 2. All participants were under 25 years of
Table 1. Participant demographic and behavioural characteristics
Total (N = 2178)a
Age 15 (14-17)
School grade
Grade 8 (13-15 years) 567 (26.03)
Grade 9 (14-16 years) 606 (27.82)
Grade 10 (16-17 years) 600 (27.55)
Grade 11 (17-18 years) 405 (18.6)
Prior pregnancyb 169 (7.76)





Missing (refused to answer) 14
Sexually active (past three months) 467 (21.57)
Missing (refused to answer) 13
aData are median (interquartile range) or N (%); bparticipants enrolled
in HPTN 068 could not be currently pregnant; cincludes non-sexual
partners.
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age. Approximately 3% reported that they were living with a
primary partner, 21% were receiving financial or material sup-
port from a partner, and 19% reported having a partner with
other partners. Furthermore, 9% of the sample had used
alcohol in the past three months and 4% were HSV-2
seropositive. Univariate analyses of individual risk factors and
HIV incidence revealed that having a partner provide financial
or material support was associated with increased risk for
HIV infection (p < .001). This finding is dissimilar to the
VOICE trial, where having a partner provide financial or
material support was found to be protective against HIV
infection.
There were 33 HIV seroconversions during 2455 person-
years of follow-up (1.34% incidence over an average follow-
up period of 1.13 years). HIV incidence by risk score is
shown in Figure 1. A majority (71%) of participants received
a risk score of 5 (range = 2-10). Scores ≥5 identified 85% of
incident infections from 94% of the sample. In the VOICE
sample, scores ≥5 identified 91% of incident infections from
only 64% of participants. Therefore, a larger proportion of
participants were categorized as being “at risk” (with a risk
score cut-point of ≥5) and, among these participants, fewer
incident infections were identified in the HPTN 068 cohort
compared with the VOICE cohort. To maximize impact and
minimize costs, biomedical HIV prevention technologies
should be offered to those at highest risk for HIV infection.
With a cut-point of ≥5, for example, 94% of the HPTN 068
sample would be eligible for PrEP.
Risk score did not predict HIV incidence (hazard ratio
(HR) = 1.029, 95% confidence interval (CI): 0.704, 1.503,
p = 0.884). Furthermore, among a subset of 528 adolescents
included in the analysis who had at least one lifetime sexual
partner at baseline, there were 18 HIV seroconversions dur-
ing 603 person-years of follow-up (2.99% incidence). The risk
score still did not predict HIV incidence (HR = 0.877, 95% CI:
0.635, 1.211, p = 0.424).
Among the 2,178 participants included in the analysis, the
AUC for the risk score was 0.55 (95% CI: 0.44, 0.65). In the
derivation and initial validation cohorts [5], all of which
included women 18 years of age or older, the risk score per-
formed more accurately. The AUC for the risk score in the
HPTN 068 sample was lower than the AUC observed in the
VOICE study (AUC = 0.71, 95% CI: 0.68, 0.74) and an exter-
nal validation in HPTN 035 (AUC = 0.70, 95% CI: 0.65, 0.75),
and similar to an external validation in FEM-PrEP
(AUC = 0.58, 95% CI: 0.51, 0.65). The predictive ability of the
risk score in the HPTN 068 cohort was also lower than a sin-
gle-item question identifying sexually active adolescent girls
(AUC = 0.65, 95% CI: 0.57, 0.74).
An analysis of additional performance characteristics for
the full sample revealed that adequate sensitivity was only
maintained under very low specificity. A risk score cut-point
of ≥5 had a sensitivity and specificity of 85% and 6%
respectively (see Table 3), with 94% PrEP eligibility. With a
cut-point of >5, however, only 23% of the sample would be
eligible for PrEP, with a sensitivity of 39% and specificity of
78%. Given the large proportion of HPTN 068 participants
who received a risk score of exactly 5 (71%), there is no
clear cut-point for identifying adolescents at risk for HIV
infection using the VOICE risk score. In the VOICE deriva-
tion cohort, a risk score cut-point of ≥5 had a sensitivity of
91% and a specificity of 38%. Furthermore, the HPTN 035
external validation cohort, which did not include alcohol use
in their risk score (maximum score = 10), had a sensitivity
and specificity of 58% and 71% respectively, with a cut-
point of ≥5. Lastly, the FEM-PrEP validation cohort, which
excluded risk factors such as alcohol use, having a partner
provide financial or material support, and HSV-2 serostatus
(maximum score = 4), had a sensitivity and specificity of
83% and 31% respectively, with a cut-point of ≥2. While
the desired sensitivity and specificity would be highly depen-
dent on the resource constraints and the availability of PrEP
in the setting in which it is being prescribed, there would
ideally be a less significant tradeoff.
Findings show that certain individual-level risk factors from
the VOICE risk score may not be relevant for adolescent pop-
ulations. For example, the entire HPTN 068 study population
was under 25 years of age (median age at base-
line = 15 years). Furthermore, the individual risk factors
derived from the VOICE study may not be relevant to the
adolescent developmental trajectory. No HPTN 068 partici-
pants were married (per inclusion criteria), less than one-third
had a primary partner, and less than one-quarter were sexu-
ally active. Therefore, questions related to cohabitation, part-
ner support, and partner behaviour may not be appropriate.
Even when only sexually active adolescents were observed,
however, the risk score still did not predict HIV incidence.
The VOICE risk-score may also not be relevant for the
HPTN 068 context. HPTN 068 enrolled adolescent girls










N (%) HR (95% CI)
Age
<25 years 2 2178 (100.00) –
≥25 years 0 0 (0.00) 1.00
Living with primary partner
No 2 2103 (96.56) 0.43 (0.13, 1.41)
Yes 0 75 (3.44) 1.00
Partner provides financial/material support
No 1 1721 (79.02) 0.31 (0.16, 0.62)*
Yes 0 457 (20.98) 1.00
Primary partner has other partners
Yes/don’t know 2 407 (18.69) 1.69 (0.82, 3.50)
No 0 1771 (81.31) 1.00
Alcohol use in past three months
Yes 1 192 (8.82) 1.36 (0.48, 3.88)
No 0 1986 (91.18) 1.00
HSV-2 seropositive
Yes 2 77 (3.54) 2.82 (0.98, 8.10)
No 0 2101 (96.46) 1.00
HR, hazard ratio; CI, confidence interval.
*p < .05.
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from a rural region in Mpumalanga province, an area charac-
terized by high HIV prevalence, poverty and migration for
work. Adolescent girls and young women in this context
may navigate partnerships differently than South African
populations more generally. While HPTN 068, the VOICE



































HIV incidence per 100 
PYS (95% CI†)
2 2 14 15.50 12.91 (3.23, 51.61)
3 0 2 2.26 0.00 
4 3 118 133.41 2.25 (0.73, 6.97)
5 15 1550 1739.61 0.86 (0.52, 1.43)
6 8 321 366.34 2.18 (1.09, 4.37)
7 3 136 155.10 1.93 (0.62, 6.00)
8 2 25 28.21 7.09 (1.77, 28.35)
9 0 11 13.30 0.00
10 0 1 1.13 0.00
†CI = Confidence Interval
Figure 1. One-year HIV incidence by risk score. CI’s calculated using the quadratic approximation to the Poisson log likelihood for the log-
rate parameter.
Table 3. Detailed sensitivity and specificity by risk score cut-point
Cut-point
Incident infections (n = 33) Non-infections (n = 2145)
Sensitivity, % Specificity, %True positives False negatives False positives True negatives
≥2 33 0 2145 0 100.00 0.00
≥3 31 2 2133 12 93.94 0.56
≥4 31 2 2131 14 93.94 0.65
≥5 28 5 2016 129 84.85 6.01
≥6 13 20 481 1664 39.39 77.58
≥7 5 28 168 1977 15.15 92.17
≥8 2 31 35 2110 6.06 98.37
≥9 0 33 12 2133 0.00 99.44
≥10 0 33 1 2144 0.00 99.95
>10 0 33 0 2145 0.00 100.00
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South Africa, there may be variability in risk factors
between study sites.
Additional risk factors should be considered when assessing
risk for HIV infection in adolescent populations. For example,
sexual debut, having multiple sexual partners (both primary
and casual partner types), and inconsistent condom use should
be explored as potential risk factors. Furthermore, risk assess-
ment tools for adolescents should consider context specific
factors in addition to age, gender, and developmentally appro-
priate factors. For example, research has demonstrated the
protective effect of schooling on HIV risk (and risk associated
with dropping out of school), especially among adolescent girls
in rural contexts [16-18]. Furthermore, research among ado-
lescent girls and young women in this context has shown that
having older partners [19,20] and engaging transactional sex
[21,22] are predictive of HIV incidence. Findings from our uni-
variate analysis also demonstrate that having a partner who
provides financial or material support is associated with
increased risk for HIV infection. In comparison to the VOICE
trial, where this factor was protective of HIV risk and sug-
gested to be a proxy for relationship stability, having a partner
provide financial or material support may be an indicator of
higher risk transactional sex among younger populations.
Lastly, in addition to identifying those at greatest risk for
HIV infection, another challenge is identifying adolescents who
perceive themselves to be at risk and thus will be likely to
adhere to a biomedical prevention technology such as PrEP
[23,24]. By balancing interest in PrEP based on perceptions of
risk and risk for HIV infection itself, a cost-effective approach
to identifying adolescents who are most likely to benefit from
the intervention can be implemented.
There are several potential limitations to this research.
First, response bias is likely to occur for sensitive questions,
especially among adolescent participants. For example, HPTN
068 participants may be more likely to under-report sexual
activity and substance use compared to older participants in
the VOICE cohort. Second, this analysis utilized data from a
trial conducted from 2011 to 2014. While the data were col-
lected several years prior to these analyses, HPTN 068
offered a large, longitudinal cohort of adolescent girls in rural
South Africa with minimal missing data and unmeasured con-
founding that we feel is still relevant to new and ongoing
PrEP implementation efforts. However, given the use of a sec-
ondary data source, there are likely differences in how individ-
ual risk factors were defined. Furthermore, HPTN 068 did not
collect data on curable STIs, a risk factor identified in the
VOICE analysis. Lastly, HPTN 068 enrolled young women who
were currently in school. Therefore, this population may be at
lower risk for engaging in certain risk behaviours compared to
young women who were not in school or who have had less
schooling, resulting in possible selection bias.
4 | CONCLUSIONS
We found that a risk score developed among adult women to
predict HIV incidence and that is being used to target PrEP
use in some settings was not helpful in identifying those at
highest risk in a population of adolescent girls in South Africa.
Findings highlight the need for an age and developmentally
appropriate tool for assessing risk for HIV infection among
adolescents in this context. Use of the VOICE risk score for
determining PrEP eligibility in younger populations should be
carefully considered.
AUTHORS ’ AFF I L IAT IONS
1Department of Epidemiology, University of North Carolina at Chapel Hill, Cha-
pel Hill, NC, USA; 2School of Health and Society, University of Wollongong, Wol-
longong, New South Wales, Australia; 3MRC/Wits Rural, Public Health and
Health Transitions Research Unit (Agincourt), Acornhoek, South Africa; 4Depart-
ment of Pathology, Johns Hopkins University, Baltimore, MD, USA; 5Fred
Hutchinson Cancer Research Center, Seattle, WA, USA; 6Department of Bio-
statistics, University of Washington, Seattle, WA, USA
COMPET ING INTERESTS
The authors declare that they have no competing interests.
AUTHORS ’ CONTR IBUT IONS
AP, KK, CM, RW, JPH and EPM designed and conducted HPTN 068, the data-
set utilized for this research. AP and DG designed the current study. DG, JW
and JPH analysed the data. DG and AP wrote the manuscript. All authors have
read, contributed to and approved the final manuscript.
ACKNOWLEDGEMENTS
This work was supported by Award Numbers UM1AI068619 (HPTN Leader-
ship and Operations Center), UM1AI068617 (HPTN Statistical and Data Man-
agement Center), and UM1AI068613 (HPTN Laboratory Center) from the
National Institute of Allergy and Infectious Diseases, the National Institute of
Mental Health and the National Institute on Drug Abuse of the National Insti-
tutes of Health. This work was also supported by NIMH R01 (R01MH087118)
and the Carolina Population Center and its NIH Center grant
(P2CHD050924). The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National Institutes of
Health.
REFERENCES
1. Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba
E, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1
serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic
Syndr. 2013;62(3):339–47.
2. Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a
clinical screening index predictive of incident HIV infection among men who
have sex with men in the United States. J Acquir Immune Defic Syndr.
2012;60(4):421–7.
3. Menza TW, Hughes JP, Celum CL, Golden MR. Prediction of HIV acquisition
among men who have sex with men. Sex Transm Dis. 2009;36(9):547.
4. Pintye J, Drake AL, Kinuthia J, Unger JA, Matemo D, Heffron R, et al. A risk
assessment tool for identifying pregnant and postpartum women who may ben-
efit from pre-exposure prophylaxis (PrEP). Clin Infect Dis. 2017;64(6):751–8.
5. Balkus JE, Brown E, Palanee T, Nair G, Gafoor Z, Zhang J, et al. An empiric
HIV risk scoring tool to predict HIV-1 acquisition in African women. J Acquir
Immune Defic Syndr. 2016;72(3):333–43.
6. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al.
Tenofovir-based preexposure prophylaxis for HIV infection among African
women. N Engl J Med. 2015;372:509–18.
7. Abdool Karim S, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T,
et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the pre-
vention of HIV infection in women. AIDS. 2011;25:957–66.
8. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Pre-
exposure prophylaxis for HIV infection among African women. N Engl J Med.
2012;367:411–22.
9. UNAIDS. AIDS by the numbers. Geneva: UNAIDS; 2016.
10. Pace JE, Siberry GK, Hazra R, Kapogiannis BG. Preexposure prophylaxis for
adolescents and young adults at risk for HIV infection: is an ounce of prevention
worth a pound of cure? Clin Infect Dis. 2013;56(8):1149–55.
11. Hosek S, Celum C, Wilson CM, Kapogiannis B, Delany-Moretlwe S, Bekker
LG. Preventing HIV among adolescents with oral PrEP: observations and chal-
lenges in the United States and South Africa. J Int AIDS Soc. 2016;19 7 Suppl
6:21107.
Giovenco D et al. Journal of the International AIDS Society 2019, 22:e25359
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25359/full | https://doi.org/10.1002/jia2.25359
5
12. HPTN 082 Uptake and adherence to daily oral PrEP as a primary preven-
tion strategy for young African women: a Vanguard Study. Available from:
https://www.hptn.org/sites/default/files/2016-05/HPTN082_FINAL_Protocol_
12082015_0.pdf
13. Kahn K, Collinson MA, Gomez-Olive FX, Mokoena O, Twine R, Mee P, et al.
Profile: agincourt health and socio-demographic surveillance system. Int J Epi-
demiol. 2012;41:988–1001.
14. Pettifor A, MacPhail C, Hughes JP, Selin A, Wang J, Gomez-Olive FX, et al.
The effect of a conditional cash transfer on HIV incidence in young women in
rural South Africa (HPTN 068): a phase 3, randomised controlled trial. Lancet
Glob Health. 2016;4(12):e978–88.
15. Pettifor A, MacPhail C, Selin A, Gómez-Olivé FX, Rosenberg M, Wagner
RG, et al. HPTN 068: a randomized control trial of a conditional cash transfer
to reduce HIV infection in young women in South Africa—study design and
baseline results. AIDS Behav. 2016;20(9):1863–82.
16. Pettifor AE, Levandowski BA, MacPhail C, Padian NS, Cohen MS, Rees HV.
Keep them in school: the importance of education as a protective factor against
HIV infection among young South African women. Int J Epidemiol. 2008;37
(6):1266–73.
17. Stoner MCD, Edwards JK, Miller WC, Aiello AE, Halpern CT, Julien A, et al.
The effect of school attendance and school drop out on incident HIV and HSV-
2 among young women in rural South Africa enrolled in HPTN 068. AIDS.
2017;31:2127–34.
18. De Neve JW, Fink G, Subramanian SV, Moyo S, Bor J. Length of secondary
schooling and risk of HIV infection in Botswana: evidence from a natural experi-
ment. Lancet Glob Health. 2015;3(8):e470–7.
19. Stoner MCD, Nguyen N, Kilburn K, Gomez-Olive FX, Edwards JK, Selin A,
et al. Age-disparate partnerships and incident HIV infection in adolescent girls
and young women in rural South Africa. AIDS. 2019;33:83–91.
20. Maughan-Brown B, George G, Beckett S, Evans M, Lewis L, Cawood C,
et al. HIV risk among adolescent girls and young women in age-disparate part-
nerships: evidence From KwaZulu-Natal, South Africa. J Acquir Immune Defic
Syndr. 2018;78(2):155–62.
21. Kilburn K, Ranganathan M, Stoner MCD, Hughes JP, MacPhail C, Agyei Y,
et al. Transactional sex and incident HIV infection in a cohort of young women
from rural South Africa. AIDS. 2018;32:1669–77.
22. Jewkes R, Dunkle K, Nduna M, Shai NJ. Transactional sex and HIV inci-
dence in a cohort of young women in the stepping stones trial. J AIDS Clin Res.
2012;3(5):158.
23. Macintyre K, Rutenberg N, Brown L, Karim A. Understanding perceptions of
HIV risk among adolescents in KwaZulu-Natal. AIDS Behav. 2004;8(3):237–50.
24. Prata N, Morris L, Mazive E, Vahidnia F, Stehr M. Relationship between
HIV risk perception and condom use: evidence from a population-based survey
in Mozambique. Int Fam Plan Perspect. 2006;32(4):192–200.
APPENDIX
Table A1. VOICE risk score




2. Married or living with husband or primary partner
No 2
Yes 0
3. Partner provides financial/material support
No 1
Yes 0










7. Any curable STIa
Yes 1
No 0
Maximum VOICE risk score 11
aChlamydia, gonorrhea, trichomoniasis, or syphilis.
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